AstraZeneca's COVID-19 Vaccine Shows Promising Response

(RTTNews) - AstraZeneca's (AZN) cornoavirus vaccine showed promising immune response in the more than 1,000 patients involved in the phase 1 and phase 2 trials.

AstraZeneca is developing a cornoavirus vaccine by the name AZD1222, in partnership with the University of Oxford.

The phase I trial data of AZD1222 was published in The Lancet medical journal on Monday. The trial demonstrated that the vaccine candidate produced antibodies and immune T-cell in participants.

"The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging," Richard Horton, the editor-in-chief of The Lancet, tweeted.

"A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunization augmenting neutralizing antibody titers," the report says.